We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Since the new administration assumed office and filled political appointments at FDA, one new emphasis seems to be assuring the prominent display of risk information in drug and device advertising
On March 30-31, FDA will hold a public meeting to discuss steps that could be taken by manufacturers of devices used in computed tomography (CT) and fluoroscopy that would help reduce unnecessary patient exposure to ionizing radiation during CT and fluoroscopic procedures
FTC is seeking comments on proposed self-regulatory guidelines submitted by i-SAFE, Inc. under the safe harbor provision of the Children's Online Privacy Protection Rule
In initial statements concerning the enforcement priorities of FDA, Commissioner Hamburg noted that enforcement letters would no longer be required to be reviewed by the Office of Chief Counsel (OCC), and that additional letters would be issued by FDA when corrections in response to warning letters were deemed sufficient by the agency
